ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 258,80
-1,04%
DAX
18 691,32
0,05%
Brent Oil
80,825
-0,86%
Bitcoin
67 845,15
-1,82%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Alligator Bioscience Ab (0RK9)

  7. Alligator Bioscience Ab (0RK9) Actualités

0RK9

Alligator Bioscience Ab (0RK9)

Alligator Bioscience Ab
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0RK9
DateHeureSourceTitreSymboleSociété
01/04/202208h20PR Newswire (US)Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort CommencesLSE:0RK9Alligator Bioscience Ab
23/03/202209h07PR Newswire (US)Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kgLSE:0RK9Alligator Bioscience Ab
11/02/202208h23PR Newswire (US)Alligator Bioscience AB: Year End report January-December 2021LSE:0RK9Alligator Bioscience Ab
01/02/202209h16PR Newswire (US)Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical OfficerLSE:0RK9Alligator Bioscience Ab
19/01/202208h42PR Newswire (US)Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory BeattyLSE:0RK9Alligator Bioscience Ab
18/01/202208h19PR Newswire (US)Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects ReportedLSE:0RK9Alligator Bioscience Ab
16/12/202108h41PR Newswire (US)Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability DataLSE:0RK9Alligator Bioscience Ab
15/12/202114h37PR Newswire (US)Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature CommunicationLSE:0RK9Alligator Bioscience Ab
08/11/202117h54PR Newswire (US)Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University RotterdamLSE:0RK9Alligator Bioscience Ab
08/11/202116h59PR Newswire (US)Bulletin from the extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
21/10/202108h45PR Newswire (US)Alligator Bioscience AB: Interim report January-September 2021LSE:0RK9Alligator Bioscience Ab
07/10/202108h25PR Newswire (US)Notice of extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
02/09/202112h17PR Newswire (US)Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipelineLSE:0RK9Alligator Bioscience Ab
02/09/202110h33PR Newswire (US)Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination TherapyLSE:0RK9Alligator Bioscience Ab
18/08/202108h50PR Newswire (US)Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion CorporationLSE:0RK9Alligator Bioscience Ab
16/08/202115h16PR Newswire (US)Alligator Bioscience Announces New Senior Director of Communications & Investor RelationsLSE:0RK9Alligator Bioscience Ab
30/06/202109h10PR Newswire (US)Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical dataLSE:0RK9Alligator Bioscience Ab
07/06/202108h25PR Newswire (US)Article on CD40 agonistic antibodies published in Expert Opinion on Biological TherapyLSE:0RK9Alligator Bioscience Ab
04/06/202108h20PR Newswire (US)Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017LSE:0RK9Alligator Bioscience Ab
05/05/202108h23PR Newswire (US)Alligator's mitazalimab shown to enhance cancer vaccineLSE:0RK9Alligator Bioscience Ab
04/05/202108h21PR Newswire (US)Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative fieldLSE:0RK9Alligator Bioscience Ab
27/04/202108h25PR Newswire (US)Alligator Bioscience AB: Interim report January-March 2021LSE:0RK9Alligator Bioscience Ab
22/04/202119h46PR Newswire (US)The Nomination Committee's proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bi...LSE:0RK9Alligator Bioscience Ab
15/04/202108h21PR Newswire (US)Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel ImmunotherapyLSE:0RK9Alligator Bioscience Ab
03/04/202114h02PR Newswire (US)Alligator Bioscience postpones the Annual General Meeting to June 1, 2021LSE:0RK9Alligator Bioscience Ab
18/03/202119h13PR Newswire (US)Alligator Bioscience appoints Søren Bregenholt as new CEOLSE:0RK9Alligator Bioscience Ab
18/03/202116h40PR Newswire (US)Alligator Bioscience publishes Annual Report for 2020LSE:0RK9Alligator Bioscience Ab
11/03/202108h21PR Newswire (US)Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACRLSE:0RK9Alligator Bioscience Ab
26/02/202108h27PR Newswire (US)Alligator Bioscience AB: Year-end Report January-December 2020LSE:0RK9Alligator Bioscience Ab
23/02/202116h12PR Newswire (US)Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA)LSE:0RK9Alligator Bioscience Ab
 Showing the most relevant articles for your search:LSE:0RK9

Dernières Valeurs Consultées

COIN
TFTEUSD
TFT on Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés